Metabolic rates of ATP transfer through creatine kinase (CK flux) predict clinical heart failure events and death

Science Translational Medicine

Volumn 5, Issue 215, 2013, Pages

  Bottomley, Paul A ^a   Panjrath, Gurusher S ^a   Lai, Shenghan ^a   Hirsch, Glenn A ^a   Wu, Katherine ^a   Najjar, Samer S ^a,b   Steinberg, Angela ^a   Gerstenblith, Gary ^a   Weiss, Robert G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE KINASE;

ADULT; AFRICAN AMERICAN; ARTICLE; ATPASE ACTIVITY ASSAY; CARDIAC IMAGING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SYNTHESIS; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE METABOLISM; HIGH ENERGY PHOSPHATE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; MIDDLE AGED; MOLECULAR DYNAMICS; PATIENT ASSESSMENT; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SYNDROME DELINEATION;

ADENOSINE TRIPHOSPHATE; ADULT; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CREATINE KINASE; DISEASE PROGRESSION; FEMALE; HEART; HEART FAILURE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MYOCARDIUM; PROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84891694472     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007328     Document Type: Article

References (39)

1. Writing Group Members, D. Lloyd-Jones, R. J. Adams, T. M. Brown, M. Carnethon, S. Dai, G. De Simone, T. B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P. M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V. L. Roger, W. Rosamond, R. Sacco, P. Sorlie, T. Thom, S. Wasserthiel-Smoller, N. D. Wong, J. Wylie-Rosett; American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 121, e46-e215 (2010).
2. J. S. Ingwall, Is cardiac failure a consequence of decreased energy reserve? Circulation 87, VII58-VII62 (1993).
3. A. M. Katz, Is the failing heart energy depleted? Cardiol. Clin. 16, 633-644 (1998).
4. J. S. Ingwall, M. F. Kramer, M. A. Fifer, B. H. Lorell, R. Shemin, W. Grossman, P. D. Allen, The creatine kinase system in normal and diseased human myocardium. N. Engl. J. Med. 313, 1050-1054 (1985).
5. T.Wallimann, M.Dolder, U. Schlattner, M. Eder, T.Hornemann, E.O'Gorman, A. Rück, D. Brdiczka, Some new aspects of creatine kinase (CK): Compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. Biofactors 8, 229-234 (1998).
6. Y. Ye, G. Gong, K. Ochiai, J. Liu, J. Zhang, High-energy phosphate metabolism and creatine kinase in failing hearts: A new porcine model. Circulation 103, 1570-1576 (2001).
7. Y. Ye, C. Wang, J. Zhang, Y. K. Cho, G. Gong, Y. Murakami, R. J. Bache, Myocardial creatine kinase kinetics and isoform expression in hearts with severe LV hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 281, H376-H386 (2001).
8. A. Gupta, A. Akki, Y. Wang, M. K. Leppo, V. P. Chacko, D. B. Foster, V. Caceres, S. Shi, J. A. Kirk, J. Su, S. Lai, N. Paolocci, C. Steenbergen, G. Gerstenblith, R. G. Weiss, Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J. Clin. Invest. 122, 291-302 (2012).
9. R. G. Weiss, G. Gerstenblith, P. A. Bottomley, ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc. Natl. Acad. Sci. U.SA. 102, 808-813 (2005).
10. C. S. Smith, P. A. Bottomley, S. P. Schulman, G. Gerstenblith, R. G. Weiss, Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114, 1151-1158 (2006).
11. M. A. Conway, J. Allis, R. Ouwerkerk, T. Niioka, B. Rajagopalan, G. K. Radda, Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338, 973-976 (1991).
12. C. J. Hardy, R. G. Weiss, P. A. Bottomley, G. Gerstenblith, Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am. Heart J. 122, 795-801 (1991).
13. S. Neubauer, T. Krahe, R. Schindler, M. Horn, H. Hillenbrand, C. Entzeroth, H. Mader, E. P. Kromer, G. A. Riegger, K. Lackner, G. Ertl, 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86, 1810-1818 (1992).
14. S. Neubauer, M. Horn, M. Cramer, K. Harre, J. B. Newell, W. Peters, T. Pabst, G. Ertl, D. Hahn, J. S. Ingwall, K. Kochsiek, Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96, 2190-2196 (1997).
15. M. Beer, T. Seyfarth, J. Sandstede, W. Landschütz, C. Lipke, H. Köstler, M. von Kienlin, K. Harre, D. Hahn, S. Neubauer, Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 40, 1267-1274 (2002).
16. M. Schär, A. M. El-Sharkawy, R. G. Weiss, P. A. Bottomley, Triple repetition time saturation transfer (TRiST) 31P spectroscopy for measuring human creatine kinase reaction kinetics. Magn. Reson. Med. 63, 1493-1501 (2010).
17. R. C. Starling, D. F. Hammer, R. A. Altschuld, Human myocardial ATP content and in vivo contractile function. Mol. Cell. Biochem. 180, 171-177 (1998).
18. M. Packer, J. R. Carver, R. J. Rodeheffer, R. J. Ivanhoe, R. DiBianco, S. M. Zeldis, G. H. Hendrix, W. J. Bommer, U. Elkayam, M. L. Kukin, G. I. Mallis, J. A. Sollano, J. Shannon, P. K. Tandon, D. L. DeMets; PROMISE Study Research Group, Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 325, 1468-1475 (1991).
19. A.M. Feldman, M. R. Bristow, W. W. Parmley, P. E. Carson, C. J. Pepine, E. M. Gilbert, J. E. Strobeck, G. H. Hendrix, E. R. Powers, R. P. Bain, B. G. White; Vesnarinone Srudy Group, Effects of vesnarinone on morbidity and mortality in patients with heart failure. N. Engl. J. Med. 329, 149-155 (1993).
20. The SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
21. M. Packer, M. R. Bristow, J.N. Cohn, W. S. Colucci, M. B. Fowler, E.M. Gilbert, N. H. Shusterman; U.S. Carvedilol Heart Failure Study Group, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334, 1349-1355 (1996).
22. M. R. Abraham, V. A. Selivanov, D. M. Hodgson, D. Pucar, L. V. Zingman, B. Wieringa, P. P. Dzeja, A. E. Alekseev, A. Terzic, Coupling of cell energetics with membrane metabolic sensing. Downloaded from stm.sciencemag.org on December 28, 2013 Integrative signaling through creatine kinase phosphotransfer disrupted by M-CK gene knock-out. J. Biol. Chem. 277, 24427-24434 (2002).
23. K. W. Saupe, M. Spindler, R. Tian, J. S. Ingwall, Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase. Circ. Res. 82, 898-907 (1998).
24. T. P. Cappola, D. A. Kass, G. S. Nelson, R. D. Berger, G. O. Rosas, Z. A. Kobeissi, E. Marbán, J. M. Hare, Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104, 2407-2411 (2001).
25. G. A. Hirsch, P. A. Bottomley, G. Gerstenblith, R. G. Weiss, Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J. Am. Coll. Cardiol. 59, 802-808 (2012).
26. G. H. Bardy, K. L. Lee, D. B. Mark, J. E. Poole, D. L. Packer, R. Boineau, M. Domanski, C. Troutman, J. Anderson, G. Johnson, S. E. McNulty, N. Clapp-Channing, L. D. Davidson-Ray, E. S. Fraulo, D. P. Fishbein, R. M. Luceri, J. H. Ip; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators, Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005).
27. F. Zannad, J. J. McMurray, H. Krum, D. J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S. J. Pocock, B. Pitt; EMPHASIS-HF Study Group, Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21 (2011).
28. S. A. Murphy, C. P. Cannon, S. D. Wiviott, C. H. McCabe, E. Braunwald, Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J. Am. Coll. Cardiol. 54, 2358-2362 (2009).
29. M. J. Tikkanen, M. Szarek, R. Fayyad, I. Holme, N. B. Cater, O. Faergeman, J. J. Kastelein, A. G. Olsson, M. L. Larsen, C. Lindahl, T. R. Pedersen; IDEAL Investigators, Total cardiovascular disease burden: Comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J. Am. Coll. Cardiol. 54, 2353-2357 (2009).
30. S. E. Nissen, Cardiovascular outcomes in randomized trials: Should time to first event for "hard" end points remain the standard approach? J. Am. Coll. Cardiol. 54, 2363-2365 (2009).
31. C. M. O 'Connor, W. T. Abraham, N. M. Albert, R. Clare, W. Gattis Stough, M. Gheorghiade, B. H. Greenberg, C. W. Yancy, J. B. Young, G. C. Fonarow, Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am. Heart J. 156, 662-673 (2008).
32. P. A. Bottomley, K. C. Wu, G. Gerstenblith, S. P. Schulman, A. Steinberg, R. G. Weiss, Reduced myocardial creatine kinase flux in human myocardial infarction: An in vivo phosphorus magnetic resonance spectroscopy study. Circulation 119, 1918-1924 (2009).
33. P. A. Bottomley, R. Ouwerkerk, R. F. Lee, R. G. Weiss, Four-angle saturation transfer (FAST) method for measuring creatine kinase reaction rates in vivo. Magn. Reson. Med. 47, 850-863 (2002).
34. R. E. Gabr, R. G. Weiss, P. A. Bottomley, Correcting reaction rates measured by saturationtransfer magnetic resonance spectroscopy. J. Magn. Reson. 191, 248-258 (2008).
35. P. A. Bottomley, C. J. Hardy, R. G. Weiss, Correcting human 31P heart spectra for partial saturation. Evidence that saturation factors for PCr/ATP are homogenous in normal and disease states. J. Magn. Reson. 95, 341-355 (1969).
36. L. J. Wei, D. Y. Lin, L. Weissfeld, Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J. Am. Stat. Assoc. 84, 1065-1073 (1989).
37. D. Y. Lin, Cox regression analysis of multivariate failure time data: The marginal approach. Stat. Med. 13, 2233-2247 (1994).
38. P. J. Kelly, L. L. Lim, Survival analysis for recurrent event data: An application to childhood infectious diseases. Stat. Med. 19, 13-33 (2000).
39. D. W. Hosmer, S. Lemeshow, Applied Survival Analysis: Regression Modeling of Time to Event Data (John Wiley & Sons, New York, 1999).